Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Posanski; Ulrich
Address:
Freiburg, DE
No. of patents:
19
Patents:












Patent Number Title Of Patent Date Issued
7511014 Cyclosporin galenic forms March 31, 2009
Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.
7235248 Pharmaceutical compositions comprising cyclosporins June 26, 2007
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2-Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weigh
7081445 Cyclosporin galenic forms July 25, 2006
Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.
6844459 Pharmaceutical Composition January 18, 2005
Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-, di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesteri
6503883 Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis January 7, 2003
The invention relates to a pharmaceutical preparation, which contains an immunosuppressive active agent in dissolved form in a starch capsule, or hard or soft gelatin capsule which has been coated with one or several polymer films. The invention further relates to a process for the p
6468968 Cyclosporin galenic forms October 22, 2002
Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.
6262022 Pharmaceutical compositions containing cyclosporin as the active agent July 17, 2001
Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-, di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesteri
6258808 Pharmaceutical composition July 10, 2001
Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-,di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesterif
6204243 Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis March 20, 2001
The invention relates to a pharmaceutical preparation, which contains an immunosuppressive active agent in dissolved form in a starch capsule, or hard or soft gelatin capsule which has been coated with one or several polymer films. The invention further relates to a process for the p
6024978 Pharmaceutical compositions comprising cyclosporins February 15, 2000
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 -alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular we
6007840 Pharmaceutical compositions comprising cyclosporins December 28, 1999
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight
5962017 Pharmaceutical compositions comprising cyclosporins October 5, 1999
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight
5962014 Pharmaceutical compositions comprising cyclosporins October 5, 1999
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight
5916589 Pharmaceutical compositions comprising cyclosporins June 29, 1999
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight
5866159 Pharmaceutical compositions comprising cyclosporins February 2, 1999
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight
5756450 Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutic May 26, 1998
A combination of a pharmacologically active compound and a water soluble monoester of a saturated or unsaturated (C.sub.6-18) fatty acid and a polyol, especially a saccharide, particularly as a solid solution of the active compound in the monoester.The solid solution is especially suitab
5741512 Pharmaceutical compositions comprising cyclosporins April 21, 1998
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight
5342625 Pharmaceutical compositions comprising cyclosporins August 30, 1994
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight
4567161 Liquid active ingredient concentrates for preparation of microemulsions January 28, 1986
Liquid, active substance formulations containing an active substance insoluble or poorly soluble in water, or a mixture, a phospholipid, a special co-emulsifier (glycerinester in which the 1 or 2 OH groups have been esterized with hydrocarbon atoms of 8-16, preferably 8-10, C atoms by










 
 
  Recently Added Patents
Quaternary chalcogenide wafers
Coreference resolution in an ambiguity-sensitive natural language processing system
Proton conducting electrolytes with cross-linked copolymer additives for use in fuel cells
Method for releasing a locking in mobile terminal and mobile terminal using the same
Power storage device and method for manufacturing the same
Lighting device with device for regulating the illumination according to the luminance of the illumination field and corresponding use
Method and apparatus for optimizing paging in a communication network
  Randomly Featured Patents
Process cartridge and image forming apparatus
Double-sided optical disc player
Center electrode assembly, nonreciprocal circuit device, communication device, and method of producing the center electrode assembly
Real time angioscopy imaging system
Wafer test system wherein period of high voltage stress test of one chip overlaps period of function test of other chip
Immunostimulating agent
Overcap
X-ray detecting device and fabricating method thereof
Electromagnetic contactor
Wet process for developing styrene polymer resists for submicron lithography